XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Operations - Stock Purchase Agreement and Series X Preferred Stock (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 28, 2021
USD ($)
shares
Feb. 28, 2021
shares
Sep. 30, 2021
shares
Jun. 30, 2021
shares
Mar. 31, 2021
USD ($)
shares
Sep. 30, 2022
shares
Sep. 30, 2021
USD ($)
Dec. 31, 2021
shares
Jun. 02, 2021
Stock Purchase Agreement and Series X Preferred Stock                  
Net proceeds from issuance of private placement | $             $ 104,261    
Beneficial conversion feature | $         $ 19,565        
Common Stock Issuable Upon Conversion at Transaction Date   14,813,954              
Minimum                  
Stock Purchase Agreement and Series X Preferred Stock                  
Common stock, percentage of beneficial ownership initially, after conversion           4.99%      
Common stock, percentage of beneficial ownership thereafter, after conversion           4.99%      
Maximum                  
Stock Purchase Agreement and Series X Preferred Stock                  
Common stock, percentage of beneficial ownership initially, after conversion           9.99%      
Common stock, percentage of beneficial ownership thereafter, after conversion           19.99%      
Shares issued in merger                  
Stock Purchase Agreement and Series X Preferred Stock                  
Common Stock Issuable Upon Conversion at Transaction Date   8,417,502              
Shares issued in February 2021 Financing                  
Stock Purchase Agreement and Series X Preferred Stock                  
Common Stock Issuable Upon Conversion at Transaction Date   5,928,952              
Warrant assumed in merger                  
Stock Purchase Agreement and Series X Preferred Stock                  
Common Stock Issuable Upon Conversion at Transaction Date   467,500              
Series X redeemable convertible preferred stock                  
Stock Purchase Agreement and Series X Preferred Stock                  
Issuance of preferred stock in a private offering of public equity, net of issuance costs (in shares)         35,573        
Number of shares of common stock into which each share of series X preferred stock may be converted           166.67      
Series X Preferred Stock at Transaction Date   88,882              
Common Stock Issuable Upon Conversion at Transaction Date           5,242,501      
Number of preferred shares converted during period           54,622      
Preferred stock, outstanding (in shares)           31,455   31,455  
Series X redeemable convertible preferred stock | Shares issued in merger                  
Stock Purchase Agreement and Series X Preferred Stock                  
Series X Preferred Stock at Transaction Date   50,504              
Series X redeemable convertible preferred stock | Shares issued in February 2021 Financing                  
Stock Purchase Agreement and Series X Preferred Stock                  
Series X Preferred Stock at Transaction Date   35,573              
Series X redeemable convertible preferred stock | Warrant assumed in merger                  
Stock Purchase Agreement and Series X Preferred Stock                  
Series X Preferred Stock at Transaction Date   2,805              
Common stock                  
Stock Purchase Agreement and Series X Preferred Stock                  
Number of shares of common stock into which each share of series X preferred stock may be converted           166.67     166.67
Common Stock Issuable Upon Conversion at Transaction Date           5,242,501      
Number of common shares issued from conversion of series X preferred stock     181,698 8,921,966   9,103,664      
Quellis Biosciences, Inc | Stock Purchase Agreement                  
Stock Purchase Agreement and Series X Preferred Stock                  
Beneficial conversion feature | $ $ 19,600                
Quellis Biosciences, Inc | Series X redeemable convertible preferred stock                  
Stock Purchase Agreement and Series X Preferred Stock                  
Number of shares of common stock into which each share of series X preferred stock may be converted 166.67                
Quellis Biosciences, Inc | Series X redeemable convertible preferred stock | Stock Purchase Agreement                  
Stock Purchase Agreement and Series X Preferred Stock                  
Issuance of preferred stock in a private offering of public equity, net of issuance costs (in shares) 35,573                
Gross proceeds from issuance of preferred stock in a private offering | $ $ 110,000                
Net proceeds from issuance of private placement | $ 104,300                
Issuance costs | $ $ 5,700                
Quellis Biosciences, Inc | Common stock | Series X redeemable convertible preferred stock                  
Stock Purchase Agreement and Series X Preferred Stock                  
Number of shares of common stock into which each share of series X preferred stock may be converted 166.67